鲁抗医药(600789) - 2017 Q1 - 季度财报

Financial Performance - Operating income decreased by 2.06% to CNY 634,047,517.68 year-on-year[6] - Net profit attributable to shareholders increased by 269.87% to CNY 11,721,799.41 compared to the same period last year[6] - Basic earnings per share rose by 228.57% to CNY 0.023 per share[6] - The diluted earnings per share also increased by 228.57% to CNY 0.023 per share[6] - Net profit for Q1 2017 reached CNY 15,246,087.82, an increase of 166.67% compared to CNY 5,720,066.24 in Q1 2016[27] - The net profit for Q1 2017 was 8,477,938.37 RMB, compared to 883,728.96 RMB in the same period last year, indicating a significant increase[31] - The total comprehensive income for the period was 8,477,938.37 RMB, reflecting a substantial improvement from 883,728.96 RMB year-over-year[31] Assets and Liabilities - Total assets increased by 5.37% to CNY 4,402,477,228.36 compared to the end of the previous year[6] - Total assets reached ¥4,402,477,228.36, up from ¥4,178,043,675.88 at the beginning of the year[21] - The company's total assets as of the end of Q1 2017 were CNY 3,764,574,051.57, up from CNY 3,584,231,575.74 at the end of Q1 2016[25] - Current liabilities totaled CNY 1,435,661,839.68, an increase of 14.77% from CNY 1,250,534,789.75 in the previous year[25] - Short-term borrowings grew by 33.11% to ¥765,407,254.00, attributed to increased bank loans[13] - Short-term borrowings rose to CNY 720,000,000.00, an increase of 30.91% from CNY 550,000,000.00 in the previous year[25] Cash Flow - Cash flow from operating activities increased by 6.03% to CNY 37,746,946.53 compared to the previous year[6] - Cash inflow from operating activities totaled 778,459,552.71 RMB, up from 732,067,262.15 RMB year-over-year, reflecting a growth of approximately 6.5%[34] - The net cash flow from operating activities was 37,746,946.53 RMB, compared to 35,601,384.29 RMB in the previous year, showing an increase of about 6%[34] - Cash and cash equivalents at the end of the period reached 560,726,996.26 RMB, up from 441,725,832.41 RMB, representing a growth of approximately 27%[35] - The company reported a net cash outflow from investing activities of 127,797,800.21 RMB, compared to a net outflow of 59,692,032.66 RMB in the previous year, indicating increased investment activity[34] - Cash inflow from financing activities was 190,407,254.00 RMB, significantly higher than 19,416,300.00 RMB in the same period last year, marking an increase of over 880%[34] - The net cash flow from financing activities was 149,878,334.46 RMB, compared to a net outflow of 32,741,138.40 RMB in the previous year, indicating a positive shift in financing[35] Shareholder Information - The number of shareholders reached 109,134 at the end of the reporting period[11] - The largest shareholder, Shandong Provincial Government, holds 24.59% of the shares[11] Investments and Expenditures - Prepayments increased by 51.52% to ¥47,195,565.43 due to higher purchase payments[13] - Engineering materials surged by 785.63% to ¥7,436,506.11 as a result of increased project investments[13] - Development expenditures rose by 43.21% to ¥25,546,873.70, reflecting higher R&D investments[13] - Other non-current assets increased by 32.66% to ¥272,741,772.76 due to higher prepayments for engineering equipment[13] - The company reported an investment income of CNY 877,750.80, up from CNY 676,835.49 in the same period last year[27] Tax and Expenses - Tax expenses rose by 77.69% to ¥6,910,835.11, mainly due to accounting policy adjustments[14] - Interest payable increased by 285.68% to ¥7,091,114.58, due to higher unpaid loan interest[13] - Asset impairment losses amounted to ¥3,942,614.93, reflecting an increase in inventory and accounts receivable impairment provisions[14] Corporate Actions - The company is in the process of a non-public offering of A-shares, pending approval from the China Securities Regulatory Commission[15]